EP3452033A4 - Pharmazeutische ophthalmische zusammensetzungen und verfahren zur herstellung davon - Google Patents
Pharmazeutische ophthalmische zusammensetzungen und verfahren zur herstellung davon Download PDFInfo
- Publication number
- EP3452033A4 EP3452033A4 EP17793224.1A EP17793224A EP3452033A4 EP 3452033 A4 EP3452033 A4 EP 3452033A4 EP 17793224 A EP17793224 A EP 17793224A EP 3452033 A4 EP3452033 A4 EP 3452033A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- fabricating
- methods
- ophthalmic compositions
- pharmaceutical ophthalmic
- pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/148,574 US20160243031A1 (en) | 2013-07-22 | 2016-05-06 | Pharmaceutical ophthalmic compositions and methods for fabricating thereof |
| US15/178,812 US20160279055A1 (en) | 2013-07-22 | 2016-06-10 | Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof |
| PCT/US2017/030772 WO2017192675A1 (en) | 2016-05-06 | 2017-05-03 | Pharmaceutical ophthalmic compositions and methods for fabricating thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3452033A1 EP3452033A1 (de) | 2019-03-13 |
| EP3452033A4 true EP3452033A4 (de) | 2020-02-12 |
Family
ID=60203416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP17793224.1A Withdrawn EP3452033A4 (de) | 2016-05-06 | 2017-05-03 | Pharmazeutische ophthalmische zusammensetzungen und verfahren zur herstellung davon |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP3452033A4 (de) |
| JP (1) | JP6694525B2 (de) |
| KR (2) | KR20190109604A (de) |
| AU (1) | AU2017260327B2 (de) |
| CA (1) | CA3023243C (de) |
| WO (1) | WO2017192675A1 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3074326A1 (en) * | 2017-09-01 | 2019-03-07 | Murray & Poole Enterprises, Ltd. | Methods and compositions for the treatment of ophthalmic conditions |
| US11071724B2 (en) | 2019-05-17 | 2021-07-27 | Ocular Science, Inc. | Compositions and methods for treating presbyopia |
| WO2021252054A1 (en) * | 2020-06-10 | 2021-12-16 | Ocular Science, Inc. | Compositions and uses in method for post-operative ocular care |
| EP4238552A1 (de) * | 2020-10-29 | 2023-09-06 | Taejoon Pharmaceutical Co., Ltd. | Ophthalmische zusammensetzung |
| WO2022156371A1 (zh) * | 2021-01-22 | 2022-07-28 | 成都瑞沐生物医药科技有限公司 | 一种眼用制剂的载体或辅料及其制备方法和应用 |
| US12594351B2 (en) | 2021-08-04 | 2026-04-07 | Harrow Ip Llc | Methods for increasing shelf-life of ophthalmic pharmaceutical compositions |
| WO2025259121A1 (en) * | 2024-06-12 | 2025-12-18 | Aft Pharmaceuticals Ltd | Vancomycin eye drops |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150025511A1 (en) * | 2013-07-22 | 2015-01-22 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical compositions for intraocular administration and methods for fabricating thereof |
| US20150164882A1 (en) * | 2013-07-22 | 2015-06-18 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical compositions for intraocular administration and methods for fabricating thereof |
| US20160101118A1 (en) * | 2014-08-15 | 2016-04-14 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical compositions for intraocular administration and methods for fabricating thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6716830B2 (en) * | 1998-09-30 | 2004-04-06 | Alcon, Inc. | Ophthalmic antibiotic compositions containing moxifloxacin |
| JP2003510263A (ja) * | 1999-09-24 | 2003-03-18 | アルコン,インコーポレイテッド | シプロフロキサシンおよびデキサメタゾンを含有する局所用懸濁処方物 |
| EP1596823A2 (de) * | 2003-02-21 | 2005-11-23 | Sun Pharmaceuticals Industries Ltd. | Stabile ophthalmische zusammensetzung |
| US20050085446A1 (en) * | 2003-04-14 | 2005-04-21 | Babu M.K. M. | Fluoroquinolone formulations and methods of making and using the same |
| US7109247B2 (en) * | 2003-05-30 | 2006-09-19 | 3M Innovative Properties Company | Stabilized particle dispersions containing nanoparticles |
| US7799331B2 (en) * | 2005-08-04 | 2010-09-21 | Taro Pharmaceutical North America, Inc. | Oral suspension of prednisolone acetate |
| BRPI0819908A2 (pt) * | 2007-11-27 | 2015-05-19 | Alcon Res Ltd | Formulações de soluções oftálmicas ou ópticas tópicas contendo cloridato de moxifloxacina e fosfato de dexametasona |
| UA119324C2 (uk) * | 2013-04-02 | 2019-06-10 | Теміс Медікер Лімітед | Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні |
| MX383077B (es) * | 2013-07-22 | 2025-03-13 | Novel Drug Solutions Llc | Composiciones farmaceuticas para la administracion intraocular que comprenden un agente antibacteriano y un agente antiinflamatorio. |
-
2017
- 2017-05-03 CA CA3023243A patent/CA3023243C/en not_active Expired - Fee Related
- 2017-05-03 AU AU2017260327A patent/AU2017260327B2/en not_active Ceased
- 2017-05-03 KR KR1020197027514A patent/KR20190109604A/ko not_active Ceased
- 2017-05-03 WO PCT/US2017/030772 patent/WO2017192675A1/en not_active Ceased
- 2017-05-03 EP EP17793224.1A patent/EP3452033A4/de not_active Withdrawn
- 2017-05-03 KR KR1020187033036A patent/KR20180126087A/ko not_active Ceased
- 2017-05-03 JP JP2018558268A patent/JP6694525B2/ja active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150025511A1 (en) * | 2013-07-22 | 2015-01-22 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical compositions for intraocular administration and methods for fabricating thereof |
| US20150164882A1 (en) * | 2013-07-22 | 2015-06-18 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical compositions for intraocular administration and methods for fabricating thereof |
| US20160101118A1 (en) * | 2014-08-15 | 2016-04-14 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical compositions for intraocular administration and methods for fabricating thereof |
Non-Patent Citations (1)
| Title |
|---|
| See also references of WO2017192675A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190109604A (ko) | 2019-09-25 |
| JP6694525B2 (ja) | 2020-05-13 |
| WO2017192675A1 (en) | 2017-11-09 |
| CA3023243A1 (en) | 2017-11-09 |
| CA3023243C (en) | 2020-01-21 |
| AU2017260327B2 (en) | 2018-12-20 |
| JP2019514975A (ja) | 2019-06-06 |
| EP3452033A1 (de) | 2019-03-13 |
| AU2017260327A1 (en) | 2018-11-29 |
| KR20180126087A (ko) | 2018-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3377040B8 (de) | Pharmazeutische verpackung für ophthalmische formulierungen | |
| EP3585433A4 (de) | Therapeutische zusammensetzungen und verwandte verfahren zur photoimmuntherapie | |
| GB201913962D0 (en) | Ophthalmic drug compositions | |
| EP3442543A4 (de) | Zusammensetzungen und verfahren für neurogenese | |
| EP3357513A4 (de) | Pharmazeutische zusammensetzung und verabreichung davon | |
| EP3452033A4 (de) | Pharmazeutische ophthalmische zusammensetzungen und verfahren zur herstellung davon | |
| EP3233111A4 (de) | Pharmazeutische zusammensetzung mit plasminogen und verwendungen davon | |
| PL3452075T3 (pl) | Oftalmiczna kompozycja farmaceutyczna | |
| EP3307265A4 (de) | Pharmazeutische kombination und verwendungen davon | |
| EP3052095A4 (de) | Epinephrinbasierte ophthalmische zusammensetzungen zur intraokularen verabreichung und verfahren zur herstellung davon | |
| EP3398598A4 (de) | Sulfonamidderivat und herstellungsverfahren und verwendung davon | |
| EP3192875A4 (de) | Pharmazeutische retard-zusammensetzung zur behandlung und vorbeugung von augenerkrankungen | |
| EP3554486A4 (de) | Pharmazeutische formulierungen zur behandlung von glaukom sowie verfahren zur herstellung und verwendung davon | |
| EP3672598A4 (de) | Arzneimittelzusammensetzungen für das auge | |
| EP3185873A4 (de) | Pharmazeutische zusammensetzung und verfahren | |
| EP3227298A4 (de) | Verfahren zur herstellung von baricitinib und zwischenprodukten davon | |
| EP3107534A4 (de) | Zusammensetzungen und verfahren zur behandlung von degenerativen erkrankungen | |
| EP3424521A4 (de) | Pharmazeutische zusammensetzung und herstellungsverfahren dafür | |
| EP3512529A4 (de) | Arzneimittelverabreichungszusammensetzungen und -verfahren | |
| EP3265103A4 (de) | Zusammensetzungen und verfahren zur behandlung von augenerkrankungen | |
| EP3554508A4 (de) | Pharmazeutische formulierungen von suvorexant | |
| EP3496714A4 (de) | Arzneimittelzusammensetzungen | |
| EP3355929A4 (de) | Neuartige ophthalmische zusammensetzung mit rebamipid und verfahren zur herstellung davon | |
| EP3533448A4 (de) | Stabile pharmazeutische zusammensetzung | |
| EP3491459A4 (de) | Ophthalmische vorrichtungen und zugehörige verfahren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20181120 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: HARROW HEALTH, INC. |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: HARROW IP, LLC |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20200115 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 38/14 20060101ALI20200109BHEP Ipc: A61K 47/10 20170101ALI20200109BHEP Ipc: A61K 31/47 20060101ALI20200109BHEP Ipc: A61K 31/4709 20060101ALI20200109BHEP Ipc: A61K 47/26 20060101ALI20200109BHEP Ipc: A61P 27/02 20060101ALI20200109BHEP Ipc: A61K 45/06 20060101ALI20200109BHEP Ipc: A61K 31/573 20060101ALI20200109BHEP Ipc: A61K 47/38 20060101ALI20200109BHEP Ipc: A61K 31/196 20060101AFI20200109BHEP Ipc: A61K 31/496 20060101ALI20200109BHEP Ipc: A61K 9/10 20060101ALI20200109BHEP |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40012052 Country of ref document: HK |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20201105 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20210316 |